Whereas pre-exposure prophylaxis (PrEP) is medication that is used to help prevent the contraction of the human immunodeficiency virus (HIV); Whereas currently PrEP is a daily pill consisting of two medications, tenofovir and emtricitabine, that an individual can take orally, which can greatly reduce the likelihood of contracting HIV; Whereas if used properly, PrEP can reduce the risk of contracting HIV from sex by up to 99 percent and can reduce the risk of contracting HIV among people who inject drugs by more than 70 percent; Whereas PrEP can be used by anyone who currently does not have HIV and is at substantial risk of contracting the virus; Whereas quarterly screening for sexually transmitted infections (STI), including testing at extra-genital sites, significantly increases detection of gonorrhea, chlamydia, and syphilis for those on PrEP, providing opportunities for prompt treatment, partner therapy, and prevention of STI-related morbidity; Whereas the Centers for Disease Control and Prevention’s HIV/AIDS prevention efforts are under the direction of the National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention whose mission includes preventing HIV infection and reducing the incidence of HIV-related illness and death; Whereas the Centers for Disease Control and Prevention is conducting projects such as Project PrIDE and Project THRIVE which work to support State and local health department demonstration projects for providing comprehensive HIV prevention and care services for the LGBTQA community and specific communities of color; Whereas the Centers for Disease Control and Prevention reported that approximately 500,000 African Americans and nearly 300,000 Latinos across the Nation could have potentially benefitted from PrEP based on CDC clinical guidelines in 2015–2016, but only 7,000 prescriptions were filled for African Americans and only 7,600 for Latinos during the same time period